It's Pharma Time: Why Merck and Lilly Are Buys, but Not Pfizer. - Barron's

Retrieved on: 2023-01-07 12:20:11

Tags for this article:

Psychoactive drugs

Tobacco

Carcinogens

Electronic cigarettes

Nicotinic agonists

Smoking cessation

Smoking

Health effects of tobacco

Click the tags to see associated articles and topics

It's Pharma Time: Why Merck and Lilly Are Buys, but Not Pfizer. - Barron's. View article details on HISWAI: https://www.barrons.com/articles/merck-lilly-pfizer-stock-pharma-51673056353

Excerpt

Whammy No. 2 for Pfizer is that it faces an estimated $17 billion in revenue declines from the loss of patent exclusivity on key drugs from 2025 to ...

Article found on: www.barrons.com

View Original Article